Monoclonal antibodies ineffective for omicron no longer authorized in US
Click Here to Manage Email Alerts
The FDA halted the use of two monoclonal antibody treatments for COVID-19 because they are not effective against the omicron variant of SARS-CoV-2, which now accounts for almost all U.S. cases.
The FDA revised the emergency use authorizations for the two treatments bamlanivimab and etesevimab administered together, and the cocktail of casirivimab and imdevimab. Their use will now be limited to infections that are likely to have been caused by a variant that is susceptible to the treatments.
Source: Adobe Stock.
“Because data show these treatments are highly unlikely to be active against the omicron variant, which is circulating at a very high frequency throughout the United States, these treatments are not authorized for use in any U.S. states, territories, and jurisdictions at this time,” Patrizia Cavazzoni, MD, director of the FDA’s Center for Drug Evaluation and Research, said in a press release.
Cavazzoni said this will avoid exposing patients to side effects from treatments “that are not expected to provide benefit to patients who have been infected with or exposed to the omicron variant.”
She said the treatments may be reauthorized in regions where patients are likely to be infected or exposed to a susceptible variant, or if they are proven affective against future variants.
The FDA noted that there are several other therapies that are expected to work against omicron, including Paxlovid, sotrovimab, remdesivir and molnupiravir.
“Health care providers should consult the NIH panel’s COVID-19 treatment guidelines and assess whether these treatments are right for their patients,” Cavazzoni said.
Perspective
Back to TopJason C. Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS
The decision by the FDA to change the emergency use authorization for bamlanivimab-etesivimab and casirivimab-imdevimab was a smart one. Unfortunately, these therapies are not active against the omicron variant that currently accounts for more than 99% of all COVID-19 cases in the U.S. Continuing to give them to patients results in a risk-benefit imbalance of all risk with no benefit and, even worse, likely stops patients from pursuing other potentially effective therapies.
The emergency use authorization is now restricted to only patients with variants known to be susceptible to these therapies, which essentially eliminates their current use. It is possible that they will be active against future variants. Fortunately, both sotrovimab and the recently authorized antivirals nirmatrelvir-ritonavir (Paxlovid) and molnupiravir are active against omicron. A future increase in the supply of these therapies would help treat patients with COVID-19 significantly, and the antivirals in particular work in such a way that they are likely to remain active against future variants.
Collapse
Read more about
Click Here to Manage Email Alerts